Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Zev Wainberg, MD, University of California Los Angeles, Los Angeles, CA, postulates on potential opportunities for advances in combination immunotherapies following positive interim results on a novel CD39 inhibitor, TTX-030. This interview took place at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, LA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.